Antihistamine Therapy: Levocetirizine in the Practice of a Family Doctor
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Allergic diseases with each passing year attract more and more attention from doctors of different specialties. Despite the fact that allergic diseases have been known to humans for more than two and a half thousand years, today’s world problems associated with the diagnosis, treatment and prevention of allergic pathologies remain very relevant. Over the past decade, the problem of allergy has embraced the scale of the global medical and social problem. At the same time allergic diseases suffer from 10–15% of the population. According to world statistics, in the structure of all allergic diseases 20–40% is allergic rhinitis (AR) and about 7–10% is bronchial asthma (BA), as well as 15% of patients with AR suffer from asthma and 76% of patients with asthma have AR. This article is based on numerous studies and emphasizes the importance of choosing the right drugs for the treatment of allergies. The Ukrainian and foreign literary sources, as well as the results of studies on the efficacy of Levzirin compared with other popular antihistamines, were studied and analyzed. Levzirin in the treatment of allergic diseases, in the complex therapy of respiratory pathology, which runs on an allergic background, demonstrates greater effectiveness in terms of suppression of the skin response to histamine than other popular H1-histamine receptor antagonists. Levzirin was more effective in influencing hyperemia compared with Loratadine. In one study, Levzirin showed a faster onset of action when the symptoms of seasonal allergic rhinitis were lessened in patients who were exposed to grass dust and also proved to be more effective than Fexofenadine, 22 hours after taking the medication and later, indicating a longer duration of action and the activity of this drug. When evaluating the effectiveness and safety of Levzirin and Olopatadine, it turned out that the latter was associated with a more pronounced side effects profile. Given the findings, Levzirin is an effective and safe agent of antihistamines of the new generation, so it is advisable to recommend it to patients with allergic diseases, which will improve their general condition and quality of life.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Аллергический ринит и его влияние на астму, 2008. В сотрудничестве с Всемирной организацией здравоохранения // Рос. аллерголог. журн. – 2010. – Т. 1. – С. 74–86.
Гуров А.В. Современные возможности диагностики и лечения аллергического ринита // РМЖ. – 2008. – Т. 16, № 2. – С. 103–105.
Лопатин А.С., Латышева Е.Н. Левоцетиризин в терапии аллергического ринита // Вестн. оториноларингол. – 2010. – № 4. – С. 98–101.
Марушко Ю.В., Шеф Г.Г. Можливості застосування левоцетиризину в терапії бронхітів та пневмоній у дітей з атопічними станами // Здоровье ребенка. – 2013. – № 4 (47). – С. 39–43.
П’ятницький Ю.С. Харчова алергія в дітей // Здоров’я України. – 2006, жовтень. – С. 31–32.
Федоскова Т.Г., Ильина Н.И. Роль аллергических заболеваний в общеклинической практике // РМЖ (Клинические рекомендации и алгоритмы для практикующих врачей, социально-значимые заболевания). – 2004. – Т. 12 (14). – С. 876–885.
Ciprandi G., Cirillo I., Vizzaccaro A., & Tosca M.A. (2004). Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. Clinical Experimental Allergy, 34(6), 958–964. doi:10.1111/j.1365-2222.2004.01960.x.
Clough G.F., Boutsiouki P., & Church M.K. (2001). Comparison of the effects of levocetirizine and loratadine on histamine-induced wheal, flare, and itch in human skin. Allergy, 56(10), 985–988. doi:10.1034/j.1398-9995.2001.00204.x.
De Blic J., Wahn U., Billard E., Alt R., & Pujazon M.-C. (2005). Levocetirizine in children: evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial. Pediatric Allergy and Immunology, 16(3), 267–275. doi:10.1111/j.1399-3038.2005.00216.x.
Denham K.J., Boutsiouki P., Clough G.F., & Church M.K. (2003). Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin. Inflammation Research, 52(10), 424–427. doi:10.1007/s00011-003-1193-5.
DuBuske L.M. (2007). Levocetirizine: The latest treatment option for allergic rhinitis and chronic idiopathic urticaria. Allergy and Asthma Proceedings, 28(6), 724–734. doi:10.2500/aap.2007.28.3051.
Frossard N., Strolin-Benedetti M., Purohit A., Pauli G. Inhibition of allergen-induced wheal and flare reactions by levocetirizine and desloratadine. Br J Clin Pharmacol. 2007;65(2):172–179. doi:10.1111/j.1365-2125.2007.03009.x.
Garry M Walsh (2008) A review of the role of levocetirizine as an effective therapy for allergic disease, Expert Opinion on Pharmacotherapy, 9:5, 859-867, DOI: 10.1517/14656566.9.5.85922.
Grant J.A., Riethuisen J.-M., Moulaert B., & DeVos C. (2002). A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Annals of Allergy, Asthma & Immunology, 88(2), 190–197. doi:10.1016/s1081-1206(10)61995-3.
Horak F., Zieglmayer P.U., Zieglmayer R., Kavina A., & Lemell P. (2005). Levocetirizine has a longer duration of action on improving total nasal symptoms score than fexofenadine after single administration. British Journal of Clinical Pharmacology, 60(1), 24–31. doi: 10.1111/j.1365-2125.2005.02377.x.
Lee H.-W., Lee H.W., Park D.J., Moon S.O., Ahn J.H., Kim M.J., Yoon Y.-R. (2008). The effects of fexofenadine at steady-state on sleep architecture: a study using polysomnography in healthy Korean volunteers. Expert Opinion on Pharmacotherapy, 9(10), 1655–1665. doi:10.1517/14656566.9.10.1655 8.
Simons FE. Advances in H1-antihistamines. N Engl J Med 2004;351:2203-17.
Mahawar D.K., Aseri M.L., Mathur S., Gaur S., Sankhla S., Dass B. A prospective study of comparison of efficacy and safety between levocetirizine and olopatadine in chronic idiopathic urticaria. Indian J Allergy Asthma Immunol 2014;28:86-92. doi:10.4103/0972-6691.140783.
McDonald K., Trick L., & Boyle J. (2008). Sedation and antihistamines: an update. Review of inter-drug differences using proportional impairment ratios. Human Psychopharmacology: Clinical and Experimental, 23(7), 555–570. doi:10.1002/hup.962.
Mösges R., König V., & Köberlein J. (2011). The Effectiveness of Levocetirizine in Comparison with Loratadine in Treatment of Allergic Rhinitis – A Meta-Analysis. Allergology International, 60(4), 541–546. doi:10.2332/allergolint.10-oa-0300.
Nettis E., Calogiuri G.F., Di Leo E., et al. Once daily levocetirizine for the treatment of allergic rhinitis and chronic idiopathic urticaria. J Asthma Allergy. 2008;2:17–23. Published 2008 Dec 16.
Pasquali M., Baiardini I., Rogkakou A., Riccio A.M., Gamalero C., Descalzi D., … Canonica G.W. (2006). Levocetirizine in persistent allergic rhinitis and asthma: effects on symptoms, quality of life and inflammatory parameters. Clinical Experimental Allergy, 36(9), 1161–1167. doi:10.1111/j.1365-2222.2006.02548.x.
Patou J., De Smedt H., van Cauwenberge P., & Bachert C. (2006). Pathophysiology of nasal obstruction and meta-analysis of early and late effects of levocetirizine. Clinical Experimental Allergy, 36(8), 972–981. doi:10.1111/j.1365-2222.2006.02544.x.
Potter P.C. (2005). Efficacy and safety of levocetirizine on symptoms and health-related quality of life of children with perennial allergic rhinitis: a double-blind, placebo-controlled randomized clinical trial. Annals of Allergy, Asthma & Immunology, 95(2), 175–180. doi:10.1016/s1081-1206(10)61208-2.
Simons F.E.R. (2007). Safety of levocetirizine treatment in young atopic children: An 18-month study. Pediatric Allergy and Immunology, 18(6), 535–542. doi:10.1111/j.1399-3038.2007.00558.x.
Staevska M., Popov T.A., Kralimarkova T., Lazarova C., Kraeva S., Popova D., … Church M.K. (2010). The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. Journal of Allergy and Clinical Immunology, 125(3), 676–682. doi:10.1016/j.jaci.2009.11.047.
